Lupin collaborates with Mark Cuban’s Cost Plus Drugs

7 Sep 2023 , 12:30 PM

On September 6, Lupin Limited announced a collaboration with American tycoon Mark Cuban’s Cost-Plus Drugs and the Florida-based non-profit COPD Foundation to increase medicine access for patients suffering from chronic obstructive pulmonary disease (COPD).

The company’s ‘unique collaboration’ with the two businesses is ‘dedicated to improving the lives of COPD patients,’ according to an announcement from the Mumbai-based drugmaker.

This collaboration intends to make Tiotropium Bromide Inhalation Powder, 18 mcg/capsule, more accessible to COPD patients in the United States, according to the company.

Lupin’s Tiotropium Bromide Inhalation Powder, 18 mcg/capsule is the only generic medicine available that is therapeutically equivalent to Spiriva HandiHaler (Tiotropium Bromide Inhalation Powder), 18 mcg/capsule by Boehringer Ingelheim Pharmaceuticals, Inc.

According to Lupin, COPD affects over 15 million adults in the United States and is the fourth biggest cause of death in the country.

At around 11.54 AM, Lupin was trading 0.36% lower at Rs 1,135 per piece, against the previous close of Rs 1,139.05 on NSE.

For feedback and suggestions, write to us at [e-mail]